Buprenorphine/Naloxone (Suboxone®)

Assessment Status NCPE Assessment Process Complete
Drug Buprenorphine/Naloxone
Brand Suboxone®
Indication Management of opiate addiction
Assessment Process
Full submission received from Applicant 02/01/2014
NCPE assessment completed 22/05/2014
NCPE assessment outcome Reimbursement Not Recommended

Pharmacoeconomic Evaluation completed in November 2007. Suboxone cannot be considered a cost effective option for patients attending HSE clinics or in the community setting in Ireland.

Technical Summary 2007


Pharmacoeconomic Reassessment completed in 2014. The NCPE does not consider Suboxone® to be cost-effective compared to methadone for the treatment of opioid dependence.

Technical Summary 2014